Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease: A meta-analysis

Circulation

Volumn 99, Issue 22, 1999, Pages 2901-2907

  Wittrup, Hans H ^a   Tybjærg Hansen, Anne ^a   Nordestgaard, Børge G ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cholesterol; Enzymes; Genetics; Heart diseases; Lipoproteins; Meta analysis

Indexed keywords

LIPID; LIPOPROTEIN; LIPOPROTEIN LIPASE;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; CORONARY RISK; GENE MUTATION; GENETIC RISK; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; META ANALYSIS; PRIORITY JOURNAL;

EID: 0033536024     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.22.2901     Document Type: Article

References (43)

1. Brunzell J. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver C, Beaudet A, Sly W, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York, NY: McGraw-Hill Inc; 1995:1913-1932.
2. Benlian P, Gennes JLD, Foubert L, Zhang H, Gagne SE, Hayden MR. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med. 1996;335:848-854.
3. Murthy V, Julien P, Gagne C. Molecular pathobiology of the human lipoprotein lipase gene. Pharmacol Ther. 1996;70:101-135.
4. Hokanson JE. Lipoprotein lipase gene variants and risk of coronary disease: a quantitative analysis of population-based studies. Int J Clin Lab Res. 1997;27:24-34.
5. Fisher RM, Humphries SE, Talmud PJ. Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. Atherosclerosis. 1997;135:145-159.
6. Paulweber B, Wiebusch H, Miesenboeck G, Funke H, Assmann G, Hoelzl B, Sippl MJ, Friedl W, Patsch JR, Sandhofer F. Molecular basis of lipoprotein lipase deficiency in two Austrian families with type I hyperlipoproteinemia. Atherosclerosis. 1991;86:239-250.
7. Wilson DE, Emi M, Iverius P-H, Hata A, Wu LL, Hillas E, Williams RR, Lalouel JM. Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation. J Clin Invest. 1990;86:735-750.
8. Galton DJ, Mattu R, Needham EW, Cavanna J. Identification of putative beneficial mutations for lipid transport. Z Gastroenterol. 1996;34(suppl 3):56-58.
9. Gerdes C, Fisher RM, Nicaud V, Boer J, Humphries SE, Talmud PJ, Faergeman O. Lipoprotein lipase variants D9N and N291S are associated with increased plasma triglyceride and lower high-density lipoprotein cholesterol concentrations: studies in the fasting and postprandial states: the European Atherosclerosis Research Studies. Circulation. 1997;96: 733-740.
10. Groenemeijer BE, Hallman MD, Reymer PW, Gagne E, Kuivenhoven JA, Bruin T, Jansen H, Lie KI, Bruschke AV, Boerwinkle E, Hayden MR, Kastelein JJ. Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients: the Ser447-stop substitution in the lipoprotein lipase gene: REGRESS Study Group. Circulation. 1997;95:2628-2635.
11. Mailly F, Tugrul Y, Reymer PW, Bruin T, Seed M, Groenemeyer BF, Asplund-Carlson A, Vallance D, Winder AF, Miller GJ, Kastelein JJP, Hamsten A, Olivecrona G, Humphries SE, Talmud PJ. A common variant in the gene for lipoprotein lipase (Asp9→Asn): functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol. 1995;15:468-478.
12. Mattu RK, Needham EW, Morgan R, Rees A, Hackshaw AK, Stocks J, Elwood PC, Galton DJ. DNA variants at the LPL gene locus associate with angiographically defined severity of atherosclerosis and serum lipoprotein levels in a Welsh population. Arterioscler Thromb. 1994;14: 1090-1097.
13. Salah D, Bohnet K, Gueguen R, Siest G, Visvikis S. Combined effects of lipoprotein lipase and apolipoprotein E polymorphisms on lipid and lipoprotein levels in the Stanislas cohort. J Lipid Res. 1997;38:904-912.
14. Wittrup HH, Tybjaerg-Hansen A, Abildgaard S, Steffensen R, Schnohr P, Nordestgaard BG. A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. J Clin Invest. 1997;99:1606-1613.
15. Mulrow CD, Oxman AD, eds. Cochrane Collaboration Handbook. Oxford, UK: Cochrane Collaboration: 1996:1-89.
16. Pimstone SN, Gagne SE, Gagne C, Lupien PJ, Gaudet D, Williams RR, Kotze M, Reymer PW, Defesche JC, Kastelein JJ, Moorjani S, Hayden MR. Mutations in the gene for lipoprotein lipase: a cause for low HDL cholesterol levels in individuals heterozygous for familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15:1704-1712.
17. Sprecher DL, Harris BV, Stein EA, Bellet PS, Keilson LM, Simbartl LA. Higher triglycerides, lower high-density lipoprotein cholesterol, and higher systolic blood pressure in lipoprotein lipase-deficient heterozygotes: a preliminary report. Circulation. 1996;94:3239-3245.
18. Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybjærg-Hansen A. Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation. 1997;96:1737-1744.
19. Elbein SC, Yeager C, Kwong LK, Lingam A, Inoue I, Lalouel JM, Wilson DE. Molecular screening of the lipoprotein lipase gene in hypertriglyceridemic members of familial noninsulin-dependent diabetes mellitus families. J Clin Endocrinol Metab. 1994;19:1450-1456.
20. de Bruin TW, Mailly F, van Barlingen HH, Fisher R, Castro Cabezas M, Talmud P, Dallinga-Thie GM. Humphries SE. Lipoprotein lipase gene mutations D9N and N291S in four pedigrees with familial combined hyperlipidaemia. Eur J Clin Invest. 1996;26:631-639.
21. Zhang Q, Cavanna J, Winkelman BR, Shine B, Gross W, Marz W, Galton DJ. Common genetic variants of lipoprotein lipase that relate to lipid transport in patients with premature coronary artery disease. Clin Genet. 1995;48:293-298.
22. Jukema JW, van Boven AJ, Groenemeijer B, Zwinderman AH, Reiber JHC, Bruschke AVG, Henneman JA, Molhoek GP, Bruin T, Jansen H, Gagné E, Hayden MR, Kastelein JJP. The Asp9Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. Circulation. 1996;94:1913-1918.
23. Mailly F, Fisher RM, Nicaud V, Luong L-A, Evans AE, Marques-Vidal P, Luc G, Arveiler D, Bard JM, Poirier O, Talmud PJ, Humphries SE. Association between the LPL-D9N mutation in the lipoprotein lipase gene and plasma lipid traits in myocardial infarction survivors from the ECTIM study. Atherosclerosis. 1996;122:21-28.
24. Zhang H, Reymer PW, Liu MS, Forsythe IJ, Groenemeyer BE, Frohlich J, Brunzell JD, Kastelein JJ, Hayden MR, Ma Y. Patients with apoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291→Ser mutation in the human LPL gene. Arterioscler Thromb Vasc Biol. 1995;15:1695-1703.
25. Reymer PW, Gagne E, Groenemeyer BE, Zhang H, Forsyth I, Jansen H, Seidell JC, Kromhout D, Lie KE, Kastelein J, Hayden MR. A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat Genet. 1995;10:28-34.
26. Fisher RM, Mailly F, Peacock RE, Hamsten A, Seed M, Yudkin JS, Beisiegel U, Feussner G, Miller G, Humphries SE, Talmud PJ. Interaction of the lipoprotein lipase asparagine 291→serine mutation with body mass index determines elevated plasma triacylglycerol concentrations: a study in hyperlipidemic subjects, myocardial infarction survivors, and healthy adults. J Lipid Res. 1995;36:2104-2112.
27. Jemaa R, Fumeron F, Poirier O, Lecerf L, Evans A, Arveiler D, Luc G, Cambou JP, Bard JM, Fruchart JC, Apfelbaum, Cambien F, Tiret L. Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels: the ECTIM study. J Lipid Res. 1995; 36:2141-2146.
28. Reymer PW, Groenemeyer BE, Gagne E, Miao L, Appelman EE, Seidel JC, Kromhout D, Bijvoet SM, van de Oever K, Bruin T, Hayden MR, Kastelein JJP. A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. Hum Mol Genet. 1995;4:1543-1549.
29. 291-Ser mutation in the lipoprotein lipase gene in two Finnish pedigrees: effect of hyperinsulinemia on the expression of hypertriglyceridemia. J Lipid Res. 1996;37: 727-738.
30. Hoffer MJV, Bredie SJH, Boomsma DI, Reymer PWA, Kastelein JJP, de Knijff P, Demacker PNM, Stalenhoef AFH, Havekes LM, Frants RR. The lipoprotein lipase (Asn291-Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidemia. Atherosclerosis. 1996;119:159-167.
31. Pimstone SN, Clee SM, Gagne SE, Miao L, Zhang H, Stein EA, Hayden MR. A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) results in altered postprandial chylomicron triglyceride and retinyl palmitate response in normolipidemic carriers. J Lipid Res. 1996; 37:1675-1684.
32. Knudsen P, Murtomäki S, Antikainen M, Ehnholm S, Lahdenperä S, Ehnholm C, Taskinen M-R. The Asn-291→Ser and Ser-447→Stop mutations of the lipoprotein lipase gene and their significance for lipid metabolism in patients with hypertriglyceridaemia. Eur J Clin Invest. 1997;27:928-935.
33. Stocks J, Thorn JA, Galton DJ. Lipoprotein lipase genotypes for a common premature termination codon mutation detected by PCR-mediated site-directed mutagenesis and restriction digestion. J Lipid Res. 1992;33:853-857.
34. Peacock RE, Hamsten A, Nilsson-Ehle P, Humphries SE. Associations between lipoprotein lipase gene polymorphisms and plasma correlations of lipids, lipoproteins and lipase activities in young myocardial infarction survivors and age-matched healthy individuals from Sweden. Atherosclerosis. 1992;97:171-185.
35. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care. 1990;6:5-30.
36. Armitage P, Berry G, eds. Statistical Methods in Medical Research. Oxford. UK: Blackwell Science Ltd; 1994:66-71, 85-88, 301-311, 527-528, 560-561.
37. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Institute. 1959;22: 719-748.
38. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
39. Barter PJ, Rye K-A. High density lipoproteins and coronary heart disease. Atherosclerosis. 1996;121:1-12.
40. Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo: molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol. 1995;15:534-542.
41. Galton DJ. Common genetic determinants of dyslipidemia: the hypertriglyceridemia/low-high-densily lipoprotein syndrome. J Cardiovasc Pharmacol. 1995;25(suppl 4):S35-S40.
42. Yang WS, Nevin DN, Peng R, Brunzell JD, Deeb SS. A mutation in the promoler of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity. Proc Natl Acad Sci U S A. 1995;92:4462-4466.
43. Hall S, Chu G, Miller G, Cruickshank K, Cooper JA, Humphries SE, Talmud PJ. A common mutation in the lipoprotein lipase gene promoter, -93T/G, is associated with lower plasma triglyceride levels and increased promoter activity in vitro. Arterioscler Thromb Vasc Biol. 1997;17:1969-1976.